Our proposed strategy to enrich for human tumor–reactive CD4+ Th cells is supported by a previous study in a mouse sarcoma model showing that neoantigen-reactive CD4+ Th cells found in the tumor expressed both PD-1 and ICOS (17). Here, CD4 is linked to sarcoma.